Core Insights - Aurion Biotech has appointed Dr. Marjan Farid as Chair of its Medical Advisory Board, bringing significant expertise in cornea, cataract, and refractive surgery to guide the company's development [1] - Dr. Farid's leadership is expected to enhance Aurion's mission to transform corneal care and restore vision for millions of patients globally [1] - Aurion is advancing its pipeline of regenerative medicines, including AURN001, an investigational cell therapy for corneal endothelial disease [1] Company Overview - Aurion Biotech is a commercial-stage regenerative cell therapy company focused on restoring vision and eliminating blindness [1] - The company is in Phase 3 development in the U.S. and has launched VyznovaTM, the first cell therapy for corneal endothelial disease commercially available in Japan [1] - Aurion received the Prix Galien award for Best Start-Up in Biotech in 2022 and was majority-owned by Alcon in 2025 [1] Leadership and Expertise - Dr. Marjan Farid is recognized as a global educator and researcher, serving as Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery [1] - Her establishment of the UCI Severe Ocular Surface Disease Program highlights her commitment to advancing patient care in ophthalmology [1] - The company emphasizes that Dr. Farid's patient-centered approach aligns with its mission to develop innovative regenerative therapies [1]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 近日 ，全球领先的眼科护理公司 爱尔康（Alcon） 宣布， 将以 最高 4.3亿美元 对价收购白内障 激光治疗设备公司 LENSAR（LNSR.O） 。而在几天后，爱尔康宣布 已成功收购眼部疾病细胞疗 法公司 Aurion Biotech 的多数股权 。 爱尔康对 Aurion 交易的财务条款尚未披露，爱尔康表示， Aurion 将在爱尔康的支持下作为独立公司运营 ，Aurion 董事会任命前首席科学官 Arnaud Lacoste 博士担任 Aurion 首席执行官，任命立即生效。 Aurion 的 AURN001 预计在 2025 年下半年启动美国 3 期试验，将利用爱尔康的全球资源和商业 专业知识， 进一步推动 AURN001 的开发和商业化 。 # 加码眼科机器人重塑市场 本次被收购的LENSAR，其核心技术是ALLY机器人白内障激光治疗系统。这是眼科领域第一款机器人白内障激光系统，主要用于治疗白内障和角膜散光；也 是 全球首个能够在一个无菌环 ...